FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2175253063> ?p ?o ?g. }

• W2175253063 endingPage "1708" @default.
• W2175253063 startingPage "1708" @default.
• W2175253063 abstract "Abstract Introduction: Rituximab-alkylator combinations are the standard therapies for patients (pts) with iNHL, however, refractory disease nearly uniformly develops. Once iNHL becomes “double-refractory” to both rituximab + alkylating agents, there are limited options to induce durable remissions. PI3K-delta signaling is critical for activation, proliferation and survival of B cells, and is hyperactive in many B-cell malignancies. Idelalisib, a selective oral inhibitor of PI3Kd, demonstrated considerable clinical activity in double-refractory iNHL (Gopal NEJM 2014). FDA granted accelerated approval for Idelalisib (Zydelig®) in patients who have received at least two prior systemic therapies with relapsed FL or SLL. Based on these encouraging initial results, we now describe long-term follow up, safety, and remission durations of this double-refractory iNHL population treated with idelalisib. Methods: Eligible iNHL pts included those with measurable disease refractory to both rituximab and an alkylating agent. Refractory was defined as lack of response to, or progression of lymphoma within 6 months of completion of index therapy, confirmed by imaging. Idelalisib 150 mg PO BID was administered continuously until disease progression or intolerance. Responses were evaluated by an independent review committee, using standard criteria (Cheson, 2007, and Owen 2013). The new data cutoff date for this analysis was June 2014, 20 months after the last patient enrolled. Results: Enrolled pts (N = 125) had a median age of 64 years and included follicular lymphoma (FL) n=72 (58%), small lymphocytic lymphoma (SLL) n=28 (22%), marginal zone lymphoma (MZL) n=15 (12%) and lymphoplasmacytic lymphoma (LPL)/Waldenstrom's macroglobulinemia (WM) n=10 (8%). The median number of prior therapies was 4 [range 2-12], including bendamustine/rituximab (BR) (n=60) and rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) (n=56) and autologous transplant (n=14). 81 pts (65%) had prior bendamustine, of which 61/81 (75%) were refractory. 112 pts (90%) were refractory to their last regimen, and 99 pts (79%) were refractory to ≥2 regimens. 38 pts (30%) had elevated LDH, and 33 pts (26%) had bulky disease >7 cm. The median time to progression from last prior therapy was 3.9 months. With a median exposure of 11.1 months (range 0.7 to 35.4), the overall response rate (ORR) is 56% (95% CI = 46.8-64.9) with 70 responders, comprising 12 CRs (9.6%), 58 PRs (46.4%). The median time to response was 1.9 months (time of first evaluation) and time to CR was 4.5 months. There were 43 pts with stable disease (SD) (34.4%). 90% of pts experienced some decrease in tumor burden. ORR for iNHL subtypes is: FL (54%), SLL (61%), MZL (47%), and LPL/WM (70%). CR rate for iNHL subtypes is: FL (14%), SLL (4%), MZL (7%), and LPL/WM (0%). Among responders, median DOR is 13.9 (0.03-31.3) months. DOR for iNHL subtypes in months (Figure 1) is: FL 11.8, SLL 13.9, MZL 18.4, and LPL/WM (not yet reached). Median PFS for all pts is 11.0 months, in comparison to a median PFS of the last prior regimen of 3.9 months (p<.0001). The median PFS for individual subtypes in months was: FL 11.0, SLL11.1, MZL 6.6, and LPL/WM 22.2. The median overall survival of all patients was 30.8 months. The adverse events include (total%/≥ grade 3%) diarrhea/colitis (50/18), fatigue (30/2), nausea (31/2), cough (32/0), pyrexia (30/2), dyspnea (18/5), rash (14/2), pneumonia (14/11), and pneumonitis (4/3). Based on central laboratory measurements, Grade ≥3 ALT/AST elevations occurred in 18 pts (14%). Drug was temporarily held in these pts, and 11/15 pts (73%) were re-treated without recurrence of ALT/AST elevation. Overall, 30 pts (24%) have discontinued therapy due to adverse events. Conclusions: The prolonged administration of idelalisib was well tolerated, had an acceptable safety profile, and was highly effective in inducing and maintaining remissions in double-refractory iNHL population with an ORR of 56%, PFS of 11 months, and DOR of 13.9 months. The response rate and long term duration of responses in the small number of subjects with LPL/WM is very promising, and will be evaluated in larger trials of this disease. The observed disease control compared to prior regimens suggests the potential for prolonged clinical benefit in this challenging patient population with unmet medical need. Figure 1: Duration of Response by Disease Group. Figure 1:. Duration of Response by Disease Group. Disclosures Gopal: Gilead Sciences: Research Funding. Off Label Use: Zydelig is a kinase inhibitor indicated for the treatment of patients with: 1) Relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities; 2) Relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patients who have received at least two prior systemic therapies; and 3) Relapsed small lymphocytic lymphoma (SLL) in patients who have received at least two prior systemic therapies.. Kahl:Gilead Sciences: Research Funding. de Vos:Gilead Sciences: Research Funding. Wagner-Johnston:Gilead Sciences: Research Funding. Schuster:Gilead Sciences: Research Funding. Jurczak:Gilead Sciences: Research Funding. Flinn:Gilead Sciences: Research Funding. Flowers:Gilead Sciences: Research Funding. Martin:Gilead Sciences: Research Funding. Viardot:Gilead Sciences: Research Funding. Blum:Gilead Sciences: Research Funding. Goy:Gilead Sciences: Research Funding. Davies:Gilead Sciences: Research Funding. Zinzani:Gilead Sciences: Research Funding. Dreyling:Gilead Sciences: Research Funding. Holes:Gilead Sciences: Employment, Equity Ownership. Sorensen:Gilead Sciences: Employment, Equity Ownership. Godfrey:Gilead Sciences: Employment, Equity Ownership. Salles:Gilead Sciences: Research Funding." @default.
• W2175253063 created "2016-06-24" @default.
• W2175253063 creator A5000959540 @default.
• W2175253063 creator A5001765276 @default.
• W2175253063 creator A5004025497 @default.
• W2175253063 creator A5013293066 @default.
• W2175253063 creator A5015361329 @default.
• W2175253063 creator A5027453053 @default.
• W2175253063 creator A5040141808 @default.
• W2175253063 creator A5046049357 @default.
• W2175253063 creator A5056946123 @default.
• W2175253063 creator A5067716137 @default.
• W2175253063 creator A5069054551 @default.
• W2175253063 creator A5069477380 @default.
• W2175253063 creator A5080630441 @default.
• W2175253063 creator A5081213752 @default.
• W2175253063 creator A5082892912 @default.
• W2175253063 creator A5085791499 @default.
• W2175253063 creator A5086354986 @default.
• W2175253063 creator A5089882481 @default.
• W2175253063 creator A5091882595 @default.
• W2175253063 date "2014-12-06" @default.
• W2175253063 modified "2023-10-16" @default.
• W2175253063 title "Mature Follow up from a Phase 2 Study of PI3K-Delta Inhibitor Idelalisib in Patients with Double (Rituximab and Alkylating agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL)" @default.
• W2175253063 doi "https://doi.org/10.1182/blood.v124.21.1708.1708" @default.
• W2175253063 hasPublicationYear "2014" @default.
• W2175253063 type Work @default.
• W2175253063 sameAs 2175253063 @default.
• W2175253063 citedByCount "11" @default.
• W2175253063 countsByYear W21752530632015 @default.
• W2175253063 countsByYear W21752530632016 @default.
• W2175253063 countsByYear W21752530632017 @default.
• W2175253063 countsByYear W21752530632020 @default.
• W2175253063 countsByYear W21752530632021 @default.
• W2175253063 crossrefType "journal-article" @default.
• W2175253063 hasAuthorship W2175253063A5000959540 @default.
• W2175253063 hasAuthorship W2175253063A5001765276 @default.
• W2175253063 hasAuthorship W2175253063A5004025497 @default.
• W2175253063 hasAuthorship W2175253063A5013293066 @default.
• W2175253063 hasAuthorship W2175253063A5015361329 @default.
• W2175253063 hasAuthorship W2175253063A5027453053 @default.
• W2175253063 hasAuthorship W2175253063A5040141808 @default.
• W2175253063 hasAuthorship W2175253063A5046049357 @default.
• W2175253063 hasAuthorship W2175253063A5056946123 @default.
• W2175253063 hasAuthorship W2175253063A5067716137 @default.
• W2175253063 hasAuthorship W2175253063A5069054551 @default.
• W2175253063 hasAuthorship W2175253063A5069477380 @default.
• W2175253063 hasAuthorship W2175253063A5080630441 @default.
• W2175253063 hasAuthorship W2175253063A5081213752 @default.
• W2175253063 hasAuthorship W2175253063A5082892912 @default.
• W2175253063 hasAuthorship W2175253063A5085791499 @default.
• W2175253063 hasAuthorship W2175253063A5086354986 @default.
• W2175253063 hasAuthorship W2175253063A5089882481 @default.
• W2175253063 hasAuthorship W2175253063A5091882595 @default.
• W2175253063 hasConcept C121332964 @default.
• W2175253063 hasConcept C126322002 @default.
• W2175253063 hasConcept C142424586 @default.
• W2175253063 hasConcept C143998085 @default.
• W2175253063 hasConcept C203014093 @default.
• W2175253063 hasConcept C2777058707 @default.
• W2175253063 hasConcept C2777938653 @default.
• W2175253063 hasConcept C2778461978 @default.
• W2175253063 hasConcept C2778714382 @default.
• W2175253063 hasConcept C2779260929 @default.
• W2175253063 hasConcept C2779338263 @default.
• W2175253063 hasConcept C2779878957 @default.
• W2175253063 hasConcept C2780653079 @default.
• W2175253063 hasConcept C2781038049 @default.
• W2175253063 hasConcept C2908647359 @default.
• W2175253063 hasConcept C2910423619 @default.
• W2175253063 hasConcept C71924100 @default.
• W2175253063 hasConcept C87355193 @default.
• W2175253063 hasConcept C90924648 @default.
• W2175253063 hasConcept C99454951 @default.
• W2175253063 hasConceptScore W2175253063C121332964 @default.
• W2175253063 hasConceptScore W2175253063C126322002 @default.
• W2175253063 hasConceptScore W2175253063C142424586 @default.
• W2175253063 hasConceptScore W2175253063C143998085 @default.
• W2175253063 hasConceptScore W2175253063C203014093 @default.
• W2175253063 hasConceptScore W2175253063C2777058707 @default.
• W2175253063 hasConceptScore W2175253063C2777938653 @default.
• W2175253063 hasConceptScore W2175253063C2778461978 @default.
• W2175253063 hasConceptScore W2175253063C2778714382 @default.
• W2175253063 hasConceptScore W2175253063C2779260929 @default.
• W2175253063 hasConceptScore W2175253063C2779338263 @default.
• W2175253063 hasConceptScore W2175253063C2779878957 @default.
• W2175253063 hasConceptScore W2175253063C2780653079 @default.
• W2175253063 hasConceptScore W2175253063C2781038049 @default.
• W2175253063 hasConceptScore W2175253063C2908647359 @default.
• W2175253063 hasConceptScore W2175253063C2910423619 @default.
• W2175253063 hasConceptScore W2175253063C71924100 @default.
• W2175253063 hasConceptScore W2175253063C87355193 @default.
• W2175253063 hasConceptScore W2175253063C90924648 @default.
• W2175253063 hasConceptScore W2175253063C99454951 @default.
• W2175253063 hasIssue "21" @default.
• W2175253063 hasLocation W21752530631 @default.
• W2175253063 hasOpenAccess W2175253063 @default.
• W2175253063 hasPrimaryLocation W21752530631 @default.

• next